Osteofibrous Dysplasia
A 13-year-old boy presents with increasing right calf mass.
History: A 13-year-old boy presents with increasing right calf mass.
Sagittal proton density image of the area of concern:
Axial fat suppressed images through the area of concern:
Diagnosis: Osteofibrous dysplasia
Findings: Cortically based lucency of the middle tibia. No medullary involvement and without periosteal reaction. Status post bone graft packing on final images.
Comments: Osteofibrous dysplasia is a rare bone tumor of the tubular bones, most commonly in the anterior cortex of the tibia, which is often referred to as an ossifying fibroma of the tubular bones. Thought to exist within a spectrum of benign to malignant with adamantinoma. Treatment is controversial but follow up radiographs and careful observation is paramount to assess for possible degeneration to adamantinoma.
Resources:
Resnick, Kransdorf, Bone and Joint Imaging 3rd Edition. 2005.
“Osteofibrous dysplasia of the tibia. Is there a need for a radical surgical approach?” Lee RS, Weitzel S, Eastwood DM, Monsell F, Pringle J, Cannon SR, Briggs TW.
“Adamantinoma of tibia: a study of 12 cases” Desai SS, Jambhekar N, Agarwal M, Puri A, Merchant N.
EMedicine.com: Osteofibrous Dysplasia
Case courtesy Hospital for Special Surgery. Click here for more Case Studies from HSS.
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
